PerkinElmer Board Declares Quarterly Dividend

4/25/23 4:05:00 PM ET

Biotechnology: Laboratory Analytical Instruments

Industrials

Get the next $PKI alert in real time by email

The Board of Directors of PerkinElmer, Inc. (NYSE:PKI) today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 11, 2023 to all shareholders of record at the close of business on July 21, 2023.

About The PerkinElmer Life Sciences and Diagnostics Company

The PerkinElmer Life Sciences and Diagnostics company – which is to be renamed during the second quarter of 2023 – provides end-to-end solutions that help scientists, researchers and clinicians better diagnose disease and discover new and more personalized drugs. The Company reported revenues of approximately $3.3 billion in 2022, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available at www.perkinelmer.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230425005745/en/

Get the next $PKI alert in real time by email

Date	Price Target	Rating	Analyst
12/19/2022	$170.00	Sector Weight → Overweight	KeyBanc Capital Markets
12/12/2022	$135.00 → $170.00	Neutral → Buy	Citigroup
12/6/2022	$192.00 → $164.00	Market Perform → Outperform	Cowen
11/28/2022	$130.00 → $145.00	Underweight → Equal Weight	Barclays
8/25/2022	$175.00	Neutral	Credit Suisse
8/18/2022	$190.00 → $170.00	Buy → Hold	Stifel
8/2/2022	$178.00	Buy → Neutral	BofA Securities
7/20/2022	$160.00	Buy	UBS

PerkinElmer Board Declares Quarterly Dividend

Chat with this insight

Recent Analyst Ratings for $PKI

$PKI SEC Filings

PerkinElmer Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

PerkinElmer Inc. filed SEC Form 8-K: Leadership Update

PerkinElmer Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

$PKI Market Insights

Live Market Insights

Analyst Ratings for Revvity

Citigroup Maintains Buy on Revvity, Lowers Price Target to $160

Stifel Maintains Hold on Revvity, Lowers Price Target to $135

$PKI Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Gonzales Anita covered exercise/tax liability with 119 shares, decreasing direct ownership by 3% to 3,591 units (SEC Form 4)

Krakowiak Maxwell covered exercise/tax liability with 85 shares, decreasing direct ownership by 1% to 7,117 units (SEC Form 4)

Klobuchar Michael A was granted 481 shares (SEC Form 4)

$PKI Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by PerkinElmer Inc. (Amendment)

SEC Form SC 13G/A filed by PerkinElmer Inc. (Amendment)

SEC Form SC 13G/A filed by PerkinElmer Inc. (Amendment)

$PKI Financials

Live finance-specific insights

Revvity Announces Financial Results for the First Quarter of 2023

Launching Revvity: A Scientific Solutions Company Powering Innovation from Discovery to Cure